Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance

New β-lactam-β-lactamase inhibitor combinations in clinical development

(2013) David M. Shlaes   Annals of the New York Academy of Sciences

In VitroActivity of Ceftaroline-Avibactam against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals from 2010 to 2012: Results from the CANWARD Surveillance Study

(2013) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World

(2013) Sarah M. Drawz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers

(2013) Jared L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases

(2013) Sushmita D. Lahiri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds

(2013) Ellie J.C. Goldstein et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Contribution of asparagine 346 residue to the carbapenemase activity of CMY-2 β-lactamase

(2013) Sandrine Dahyot et al.   FEMS MICROBIOLOGY LETTERS

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

(2013) David E. Ehmann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value

(2013) Robert K. Flamm et al.   JOURNAL OF CHEMOTHERAPY

New antibiotics for bad bugs: where are we?

(2013) Matteo Bassetti et al.   Annals of Clinical Microbiology and Antimicrobials

“Stormy waters ahead”: global emergence of carbapenemases

(2013) Gopi Patel et al.   Frontiers in Microbiology

In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates

(2012) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

(2011) Ken Coleman   CURRENT OPINION IN MICROBIOLOGY

Increasing prevalence and dissemination of NDM-1 metallo- -lactamase in India: data from the SMART study (2009)

(2011) C. Lascols et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

NXL104, un nouvel inhibiteur de β-lactamases à large spectre

(2011) V. Cattoir   Journal des Anti-infectieux

The coming of age of antibiotics: discovery and therapeutic value

(2010) Karen Bush   Annals of the New York Academy of Sciences

Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative Bacteria

(2010) Karen Bush et al.   Annual Review of Microbiology

Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam  -Lactamase Inhibitor

(2010) T. Stachyra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular Basis for Drug Resistance in HIV-1 Protease

(2010) Akbar Ali et al.   Viruses-Basel

Extended-Spectrum Cephalosporinases in Pseudomonas aeruginosa

(2009) J.-M. Rodriguez-Martinez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

AmpC  -Lactamases

(2009) G. A. Jacoby   CLINICAL MICROBIOLOGY REVIEWS

Re-examining the role of Lys67 in class C β-lactamase catalysis

(2009) Yu Chen et al.   PROTEIN SCIENCE

Contribution of extended-spectrum AmpC (ESAC) β-lactamases to carbapenem resistance in Escherichia coli

(2008) Hedi Mammeri et al.   FEMS MICROBIOLOGY LETTERS